Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 3/20 | 0.51 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27546311 | 0.85 | IDO1 (0.54) | IDO1DAOPDE2APTPN1GSK3B | |
| SCHEMBL1117948 | 0.84 | IDO1 (0.58) | IDO1DAOPDE2APTPN1GSK3B | |
| SCHEMBL5426147 | 0.82 | IDO1 (0.61) | IDO1DAOPDE2ASLC6A4SLC6A2 | |
| SCHEMBL3632101 | 0.81 | IDO1 (0.54) | IDO1DAOPDE2ASLC6A4SLC6A2 | |
| SCHEMBL2600180 | 0.81 | IDO1 (0.54) | IDO1DAOPDE2ASLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL4496729 | 0.81 | IDO1 (0.64) | IDO1DAOPDE2ASLC6A4SLC6A2 | |
| SCHEMBL18097379 | 0.81 | IDO1 (0.54) | IDO1DAOPDE2ASLC6A4SLC6A2 | |
| SCHEMBL27975927 | 0.81 | DAO (0.51) | IDO1DAOPTPN1GSK3BSLC6A4 | |
| SCHEMBL5426897 | 0.79 | DAO (0.52) | IDO1DAOPDE2APTPN1GSK3B | |
| SCHEMBL23891924 | 0.78 | IDO1 (0.56) | IDO1DAOPDE2ATAAR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3285581-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| CN-105473575-A | Benzimidazolyl-methylurea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD | 2016-04-06 | — | — | CN | disclosed |
| CN-101626685-B | N-substituted glycine derivatives: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2013-03-13 | — | — | CN | disclosed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | IDO1 2203/4885DAO 4029/4885PDE2A 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.